DrugLib.com — Drug Information Portal

Rx drug information, pharmaceutical research, clinical trials, news, and more

Atropine Effects in Anaesthesia With Sufentanil vs. Remifentanil

Information source: University Medical Center Groningen
ClinicalTrials.gov processed this data on August 23, 2015
Link to the current ClinicalTrials.gov record.

Condition(s) targeted: Haemodynamic Fluctuations During Off-pump CABG.

Intervention: Remifentanil (Drug); Sufentanil (Drug)

Phase: N/A

Status: Recruiting

Sponsored by: University Medical Center Groningen

Official(s) and/or principal investigator(s):
Alain F Kalmar, MD, PhD, Principal Investigator, Affiliation: University Medical Center Groningen

Overall contact:
Alain F Kalmar, MD, PhD, Email: a.f.kalmar@umcg.nl


Induction of general anaesthesia with a combination of opiates and hypnotics often induces vasodilation resulting in several haemodynamic effects such as a decrease in blood pressure (MAP), heart rate (HR) and cardiac output (CO). This haemodynamic suppression may jeopardize tissue oxygenation, particularly cerebral oxygenation. Previous research of the investigators group has revealed that atropine has an exceptionally beneficial effect on the determinants of tissue oxygen delivery as well as on tissue oxygenation. The investigators have demonstrated a significant and clinically relevant increase in CO and cerebral tissue oxygenation (SctO2) for a desired increase in MAP. This is in steep contrast with the more usual clinical practice of administrating classical vasoactive medication such as phenylephrine or norepinephrine, since the two latter have an even negative effect on CO and SctO2. In previous research the investigators used standardized target controlled propofol/remifentanil infusions for induction and maintenance of anaesthesia. It is known that remifentanil has more intense haemodynamic side-effects compared to other opiates such as fentanyl, sufentanil or alfentanil. This raises the question whether the beneficial effect of atropine is restricted to propofol/remifentanil anaesthesia, or if this is equally valid during anaesthesia of propofol combined with other opiates such as sufentanil. Patients undergoing off-pump coronary artery bypass grafting (CABG) require a long and deep general anaesthesia, which is usually performed with the combination of drugs as mentioned above. Because these patients often experience severe haemodynamic fluctuations they need to be closely monitored.

Clinical Details

Official title: Comparison of the Effects of Atropine on Haemodynamics and Tissue Oxygenation in Anaesthesia With Propofol and Sufentanil Versus Propofol and Remifentanil

Study design: Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment

Primary outcome: CO

Secondary outcome:


Tissue oxygen saturation



Minimum age: 18 Years. Maximum age: N/A. Gender(s): Both.


Inclusion Criteria:

- Age: 18 years and older.

- Elective CABG surgery performed off-pump.

- Written informed consent to participate in this study.

- Patient and surgical procedure appropriate for treatment with either sufentanil or

remifentanil. Exclusion Criteria:

- Refusal to participate in this study.

- Age: younger than 18 years.

- Pregnant.

- BMI > 35 kg/m2.

- Patients in which atropine is contra-indicated.

- Patients in which sufentanil or remifentanil at the proposed doses are


- Urgent or emergency surgery.

Locations and Contacts

Alain F Kalmar, MD, PhD, Email: a.f.kalmar@umcg.nl

University Medical Center Groningen, Groningen 9713GZ, Netherlands; Recruiting
Rob Spanjersberg, Email: r.spanjersberg@umcg.nl
Alain F Kalmar, MD, PhD, Principal Investigator
Additional Information

Starting date: June 2013
Last updated: January 30, 2014

Page last updated: August 23, 2015

-- advertisement -- The American Red Cross
Home | About Us | Contact Us | Site usage policy | Privacy policy

All Rights reserved - Copyright DrugLib.com, 2006-2017